Literature DB >> 24861565

The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis.

Andrea Navarria1, Alessandra Tamburella1, Fabio A Iannotti2, Vincenzo Micale3, Giovanni Camillieri1, Lucia Gozzo1, Roberta Verde2, Roberta Imperatore2, Gian Marco Leggio1, Filippo Drago1, Vincenzo Di Marzo4.   

Abstract

In recent years, several studies have explored the involvement of the deregulation of the hypothalamus-pituitary-adrenal (HPA) axis in the pathophysiology of stress-related disorders. HPA hyper-activation as a consequence of acute/chronic stress has been found to play a major role in the neurobiological changes that are responsible for the onset of such states. Currently available medications for depression, one of the most relevant stress-related disorders, present several limitations, including a time lag for treatment response and low rates of efficacy. N-Arachidonoylserotonin (AA-5-HT), a dual blocker at fatty acid amide hydrolase (FAAH, the enzyme responsible for the inactivation of the endocannabinoid anandamide) and transient receptor potential vanilloid type-1 channel (TRPV1), produces anxiolytic-like effects in mice. The present study was designed to assess the capability of AA-5-HT to reverse the behavioral despair following exposure to stress in rats and the role of the HPA-axis. Behavioral tasks were performed, and corticosterone and endocannabinoid (anandamide and 2-arachidonoylglycerol) levels were measured in selected brain areas critically involved in the pathophysiology of stress-related disorders (medial PFC and hippocampus) under basal and stress conditions, and in response to treatment with AA-5-HT. Our data show that AA-5-HT reverses the rat behavioral despair in the forced swim test under stress conditions, and this effect is associated with the normalization of the HPA-axis deregulation that follows stress application and only in part with elevation of anandamide levels. Blockade of FAAH and TRPV1 may thus represent a novel target to design novel therapeutic strategies for the treatment of stress-related disorders.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FAAH; HPA-axis; N-Arachidonoylserotonin; Stress; TRPV1

Mesh:

Substances:

Year:  2014        PMID: 24861565     DOI: 10.1016/j.phrs.2014.04.014

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  23 in total

1.  Effects of intranasal administration of the peptide antagonist of type I vaniloid receptor (TRPV1) in the rodent central nervous system.

Authors:  A O Tishkina; E K Mart'yanova; Yu A Logashina; Ya A Andreev; S F Khaibullina; E V Martynova; A A Rizvanov; N V Gulyaeva; E V Grishin
Journal:  Dokl Biol Sci       Date:  2016-11-08

Review 2.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

Review 3.  Neurobiological Interactions Between Stress and the Endocannabinoid System.

Authors:  Maria Morena; Sachin Patel; Jaideep S Bains; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

Review 4.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 5.  Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence.

Authors:  Uri Bright; Irit Akirav
Journal:  Int J Mol Sci       Date:  2022-05-15       Impact factor: 6.208

Review 6.  The Endocannabinoids-Microbiota Partnership in Gut-Brain Axis Homeostasis: Implications for Autism Spectrum Disorders.

Authors:  Roberto Coccurello; Maria Cristina Marrone; Mauro Maccarrone
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

Review 7.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

Review 8.  Integrating endocannabinoid signaling in the regulation of anxiety and depression.

Authors:  An-Qi Yin; Feng Wang; Xia Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-07-12       Impact factor: 6.150

Review 9.  Integrating Endocannabinoid Signalling In Depression.

Authors:  Tarapati Rana; Tapan Behl; Aayush Sehgal; Vineet Mehta; Sukhbir Singh; Ravinder Kumar; Simona Bungau
Journal:  J Mol Neurosci       Date:  2021-01-20       Impact factor: 3.444

Review 10.  High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity.

Authors:  Marie Fitzgibbon; David P Finn; Michelle Roche
Journal:  Int J Neuropsychopharmacol       Date:  2015-09-05       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.